Sun Pharma Advanced Research Company Ltd
Sun Pharma Advanced Research Company Ltd Q1 FY21 Results & Presentation Highlights: Revenue, Margins & Order Book
Q1 FY21 investor presentation: what the company reported on revenue, margins and projects.
Based on Sun Pharma Advanced Research Company Ltd's Q1 FY21 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1 FY21 Total Income: INR 1,861 Mn (~$24.5 Mn), up from Q1 FY20 Total Income: INR 210 Mn (~$3.0 Mn), indicating a significant year-on-year increase primarily due to a non-recurring upfront payment. The presentation does not explicitly report EBITDA or operating margin figures for the quarter.
From Sun Pharma Advanced Research Company Ltd's Q1 FY21 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Q1 FY21 Total Income: INR 1,861 Mn (~$24.5 Mn), up from Q1 FY20 Total Income: INR 210 Mn (~$3.0 Mn), indicating a significant year-on-year increase primarily due to a non-recurring upfront payment.
- Total Expenses in Q1 FY21: INR 1,294 Mn (~$17.1 Mn) vs Q1 FY20: INR 1,152 Mn (~$16.6 Mn).
- Profit after Tax in Q1 FY21: INR 567 Mn (~$7.5 Mn) vs loss of INR 942 Mn (~$-13.5 Mn) in Q1 FY20, reflecting turnaround due to a $20 Mn upfront licensing payment from SCD-044.
- No explicit quantitative outlook for revenue or volumes is stated; however, FY21 budget allocates ~60% of spend to clinical expenses.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Sun Pharma Advanced Research Company Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sun Pharma Advanced Research Company Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Sun Pharma Advanced Research Company Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.9K Cr, net profit ₹1.8K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sun Pharma Advanced Research Company Ltd's management said in earlier quarters
Frequently Asked Questions
What were Sun Pharma Advanced Research Company Ltd Q1 FY21 results?
Q1 FY21 Total Income: INR 1,861 Mn (~$24.5 Mn), up from Q1 FY20 Total Income: INR 210 Mn (~$3.0 Mn), indicating a significant year-on-year increase primarily due to a non-recurring upfront payment. The presentation does not explicitly report EBITDA or operating margin figures for the quarter.
What is Sun Pharma Advanced Research Company Ltd share price analysis?
Sun Pharma Advanced Research Company Ltd currently shows a neutral. The stock trades at a P/E of 3.9 with a market cap of ₹6,293 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sun Pharma Advanced Research Company Ltd planning capital expenditure?
The presentation does not describe any specific capex, capacity expansion, or new plant/project details including amounts, status, or timelines.
Keep Sun Pharma Advanced Research Company Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.